IMC Chicago
NVCR icon

IMC Chicago’s NovoCure NVCR Stock Holding History

IMC Chicago’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$339K Sell
31,100
-1,800
-5% -$22.5K ﹤0.01% 4453
2025
Q4 		$425K Buy
32,900
+4,400
+15% +$56.5K ﹤0.01% 3585
2025
Q3 		$368K Buy
28,500
+17,100
+150% +$228K ﹤0.01% 3339
2025
Q2 		$203K Buy
+11,400
New +$199K ﹤0.01% 3259
2025
Q1 		– Sell
-19,800
Closed -$590K – 3361
2024
Q4 		$590K Buy
19,800
+4,300
+28% +$91K ﹤0.01% 2663
2024
Q3 		$242K Buy
+15,500
New +$281K ﹤0.01% 2701

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

IMC Chicago's NVCR Position: Q1 2026 in Review

IMC Chicago reduced its NovoCure (NVCR) stake by 27% in Q1 2026, selling an estimated $140K and leaving 30,692 shares worth $335K. The position accounts for ﹤0.01% of the portfolio, ranked #4465.

IMC Chicago first reported a position in NVCR in Q2 2025 and has held it in 4 quarters since. The position peaked at $542K in Q4 2025. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • IMC Chicago held 30,692 shares of NovoCure worth $335K as of Q1 2026.
  • IMC Chicago sold 11,217 NovoCure shares in Q1 2026, an estimated $140K.
  • NovoCure made up ﹤0.01% of IMC Chicago's portfolio in Q1 2026, its #4465 holding.
  • IMC Chicago first reported a position in NovoCure in Q2 2025 and has held it in 4 quarters since.
  • IMC Chicago's NovoCure position peaked at $542K in Q4 2025.
  • 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on IMC Chicago's 13F filing for Q1 2026, filed 5 May 2026.